CNTF: Product race, patent risk
By Eric Pierce
Staff Writer

There's a good chance a CNTF product with Orphan Drug status could reach the market two to three years before the long anticipated interference between Synergen Inc.'s issued patent and Regeneron Pharmaceuticals Inc.'s allowed patent on the CNTF gene can be resolved.